Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock, $0.001 par value per share · CUSIP: 05338F306
Event date: 2026-01-22
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Affinity Asset Advisors, LLC
Shares: 1,051,054 · Class: 5.7%
- Michael Cho
Shares: 1,051,054 · Class: 5.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001315863-26-000095
- Form type
- SCHEDULE 13G/A
- Filer
- Affinity Asset Advisors, LLC
- CIK
- CIK 1773195
- Filed
- Jan 29, 2026
- Reporting period
- Jan 22, 2026
- Description
- Schedule 13G beneficial ownership